Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ATRA on Nasdaq
Shares outstanding
7,230,838
Price per share
$5.00
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,049,655
Total reported value
$37,062,796
% of total 13F portfolios
0%
Share change
+166,547
Value change
+$3,113,209
Number of holders
40
Price from insider filings
$5.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% 0% $10,764,875 +$659,400 751,223 +6.5% Redmile Group, LLC 12 Nov 2025
EcoR1 Capital, LLC 9.9% $10,258,030 715,853 EcoR1 Capital, LLC 30 Sep 2025
Panacea Innovation Ltd 9.5% $4,180,000 550,000 Panacea Venture Healthcare Fund II, L.P. 30 Jan 2025

As of 31 Dec 2025, 40 institutional investors reported holding 2,049,655 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 28% of the company’s total 7,230,838 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) together control 28% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
EcoR1 Capital, LLC 7.9% 573,183 0% 0.48% $10,368,880
Redmile Group, LLC 6.1% 441,701 0% 0.59% $7,990,371
VANGUARD GROUP INC 3.1% 225,940 +11% 0% $4,087,255
MARSHALL WACE, LLP 2.1% 148,632 +28% 0% $2,688,752
GLOBEFLEX CAPITAL L P 1.1% 77,224 +400% 0.21% $1,396,982
BlackRock, Inc. 0.93% 67,108 -3.9% 0% $1,213,984
GEODE CAPITAL MANAGEMENT, LLC 0.86% 62,381 +3.1% 0% $1,129,112
MACKENZIE FINANCIAL CORP 0.81% 58,668 -8.1% 0% $1,046,920
ACADIAN ASSET MANAGEMENT LLC 0.75% 54,048 -4.2% 0% $976,000
STALEY CAPITAL ADVISERS INC 0.69% 50,000 0% 0.04% $904,500
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.45% 32,691 +134% 0.01% $591,380
RENAISSANCE TECHNOLOGIES LLC 0.42% 30,040 +59% 0% $543,424
STATE STREET CORP 0.37% 26,453 +4.8% 0% $478,535
Cambridge Investment Research Advisors, Inc. 0.32% 22,864 +34% 0% $414,000
Quadrature Capital Ltd 0.28% 20,321 +23% 0% $367,607
Point72 Asset Management, L.P. 0.25% 18,296 0% $330,975
FMR LLC 0.24% 17,156 0% 0% $310,352
MORGAN STANLEY 0.22% 15,991 -56% 0% $289,276
CITADEL ADVISORS LLC 0.22% 15,577 0% $281,788
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.19% 14,018 0% $253,586
JANE STREET GROUP, LLC 0.19% 13,990 -37% 0% $253,080
NORTHERN TRUST CORP 0.17% 12,340 +12% 0% $223,231
Walleye Capital LLC 0.17% 12,169 0% $220,137
Connor, Clark & Lunn Investment Management Ltd. 0.14% 10,446 0% $188,968
BANK OF AMERICA CORP /DE/ 0.14% 10,387 +78% 0% $187,901

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,049,655 $37,062,796 +$3,113,209 $18.09 40
2025 Q3 1,883,136 $26,983,314 +$1,944,887 $14.33 36
2025 Q2 1,803,350 $13,921,685 -$1,938,164 $7.72 32
2025 Q1 2,086,793 $12,393,904 -$4,023,428 $5.94 36
2024 Q4 2,368,286 $31,519,295 -$410,987 $13.31 41
2024 Q3 2,414,500 $19,628,975 -$1,762,796 $8.13 33
2024 Q2 2,653,675 $22,554,322 +$22,225,788 $8.50 43